Jefferies Says That Abiomed (ABMD) Run is 'Just Getting Started'
Tweet Send to a Friend
Jefferies reiterates their Buy rating on Abiomed (NASDAQ: ABMD) and raise the price target to $83 (from $72) saying that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
